Rhythm Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $139.47. The average 1-year stock price forecast is 26.32% higher than the current stock price, while the lowest is $105 (-4.90%) and the highest is $159 (+44.01%).

Price Target: $139.47 (+26.32%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$105	$139.47	$142	$159
Change	-4.90%	+26.32%	+28.61%	+44.01%

Analyst Ratings

The average analyst rating for Rhythm Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	11	11	11	11	11	11
Buy	3	4	4	4	4	4
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	16	16	16	16	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Phil Nadeau TD Cowen	TD Cowen	Buy Maintains $130	Buy	Maintains	$130	+17.74%	Jun 17, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $143 → $151	Buy	Maintains	$143 → $151	+36.76%	Jun 16, 2026
Dennis Ding Jefferies	Jefferies	Buy Maintains $125	Buy	Maintains	$125	+13.21%	Jun 15, 2026
Corinne Johnson Goldman Sachs	Goldman Sachs	Buy Maintains $158 → $159	Buy	Maintains	$158 → $159	+44.01%	Jun 15, 2026
Michael Ulz Morgan Stanley	Morgan Stanley	Buy Reiterates $136	Buy	Reiterates	$136	+23.18%	Jun 15, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

298.08M

from 189.76M

57.08%

from 189.76M

Revenue Next Year

539.23M

from 298.08M

80.90%

from 298.08M

EPS This Year

-3.26

from -3.11

EPS Next Year

-0.74

from -3.26

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	3.15M	23.64M	77.43M	130.13M	189.76M	298.08M
Revenue Growth	-	649.46%	227.56%	68.06%	45.83%	57.08%
Gross Profit	2.56M	21.51M	68.13M	116.76M	170.27M	268.77M
Gross Margin	81.01%	90.98%	87.99%	89.73%	89.73%	90.17%
Operating Income	-170.06M	-179.16M	-184.36M	-173.10M	-192.02M	-211.19M
Net Income	-69.61M	-181.12M	-184.68M	-260.60M	-196.54M	-215.90M
EPS	-	-	-	-	-3.11	-3.26
Free Cash Flow	-57.05M	-105.11M	-91.47M	-81.99M	-145.98M	-218.33M
No. Analysts	-	-	-	-	-	16

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	321.0M
Avg	298.1M
Low	273.6M

Revenue Growth

Revenue Growth	2026	2027	2028
High	69.2%
Avg	57.1%
Low	44.2%

EPS Forecast

EPS	2026	2027	2028
High	-2.45
Avg	-3.26
Low	-4.02

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-